Anticalins: Inhalable Biologicals For Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$577,933.00
Summary
This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.
The project aims to improve cochlear implant performance via integrated gene therapy. A neurotrophin gene cassette will be delivered to cells adjacent to the electrode array using electrical pulses. This drives regeneration of the auditory nerve fibres and considerably improves cochlear implant performance. This study will optimize the therapeutic gene construct and cochlear implant –based gene delivery controller, and undertake an initial clinical trial to evaluate safety and efficacy.
Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Cachexia is a major side effect of cancer, resulting in significant muscle wasting, fat loss and organ failure. Up to 80% of cancer patients suffer and 25% succumb to this condition. This significantly affects the treatment regimens of cancer patients and affects their quality of life. We have developed monoclonal antibodies that block and reverse cachexia in preclinical mouse cancer models. Our aims are to humanise the antibody and manufacture it for the first clinical trial in humans.
Development Of Stable Human Antibody Phage Display Libraries
Funder
National Health and Medical Research Council
Funding Amount
$539,644.00
Summary
Antibodies are blockbuster therapeutics for the treatment of cancer and inflammation. Unfortunately, they often display limited stability which greatly hinders development and production. This project focuses on the construction of large libraries of stable antibodies, thereby streamlining the development of new therapeutics.
X-Tream: A Realtime X-ray Treatment Monitoring And Dosimetry System For Submillimetric Radiosurgery
Funder
National Health and Medical Research Council
Funding Amount
$408,544.00
Summary
We plan to develop a commercial prototype of a new clinical product called X-Tream, together with pre-clinical experimental and Monte Carlo data to demonstrate its performance in one potential clinical application involving an exciting and rapidly developing radiosurgery technique known as microbeam radiation therapy. We intend to show that the X-Tream system has the demonstrated ability to provide essential measurements with the necessary accuracy to allow for future clinical trials.
Development Of An Intra-Operative Tool For Tumour Margin Assessment During Surgery
Funder
National Health and Medical Research Council
Funding Amount
$599,472.00
Summary
The objective of this study is to develop and evaluate a surgical probe that uses novel terahertz technology to guide surgical excision. As an example, approximately 3,000 breast cancer patients per year require a second surgical procedure because of tumour identified close to the edge of tissue removed during surgery. There is a clinical need for an accurate, real-time and non-destructive technique to assess tumour margins during surgery. This tool could also be used for any surgery that requir ....The objective of this study is to develop and evaluate a surgical probe that uses novel terahertz technology to guide surgical excision. As an example, approximately 3,000 breast cancer patients per year require a second surgical procedure because of tumour identified close to the edge of tissue removed during surgery. There is a clinical need for an accurate, real-time and non-destructive technique to assess tumour margins during surgery. This tool could also be used for any surgery that requires preservation of normal tissue.Read moreRead less
We will create a new class of cancer radiotherapy system that solves the complex problem of how to target a tumour with precision and accuracy even as the patient’s anatomy changes during treatment. Our Nano-X system is built with real-time imaging guidance and treatment adaptation at the heart of the design process; and complex processing tasks have been moved from hardware to software, enabling radical changes to machine design. Together these innovations will ensure better treatment outcomes.
Superior Surgical Fixation Using A Novel Orthopaedic Expandable Fastener
Funder
National Health and Medical Research Council
Funding Amount
$414,076.00
Summary
Surgeons repair bone fractures using metal plates and screws. Sometimes the screws loosen and the surgery needs to be repeated. Expandable screws are stronger, but more difficult and sometimes impossible to remove. The research team will test a new type of screw that holds the bones together with greater strength (our current work shows 40% stronger) but can be removed easily if necessary. This grant will allow extensive mechanical testing in preparation for a first-in-human clinical trial.
Breathe Well: Improving Cancer Imaging And Targeted Radiotherapy Using Audiovisual Biofeedback
Funder
National Health and Medical Research Council
Funding Amount
$606,847.00
Summary
Irregular breathing causes anatomical errors in medical images and consequently cancer targeting accuracy, resulting in poorer clinical outcomes and increased health care costs. We have developed and patented the Breathe Well Audio Visual (AV) biofeedback device, to improve breathing regularity. Our goal is to gather critical scientific information and reach commercial proof-of-concept objectives that will allow us to attract investment to establish a viable medical device enterprise.